The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
Stryker Corporation SYK
Clears both ethical standards
An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Stryker Corporation operates as a medical technology company in the United States and internationally.
read at $337.03
Stryker Corporation holds its Markup at $337.03.
- PHPhase · the trend structure carries the Markup label
- INInsiders · no filings inside 60 days, left as found
- POPositioning · no disclosures inside 60 days, left as found
- OPOptions · no verdict drawn today, left as found
- SCScreen · passes the values gate
- edge confirmed
- edge broken
- edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
The investor read · the season, not the day
| Phase | Markup |
| Quantitative state | Consolidating, no directional conviction, held for 1 days |
| Price | $337.03 |
| Valuation | 34.96 trailing · 20.11 forward price to earnings |
| Values screen | PASS · score 83.2 |
| Beta | 0.77 |
The opportunity · what the numbers say it is worth
Our framework reads OVERVALUED — it trades at roughly a 11% discount to our $374.84 fair value, moderate competitive moat, 9.40% revenue growth.
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
| Revenue growth | 9.40% |
| Profit margin | 14.43% |
| Debt to equity | 64.39 |
| Analyst consensus | Buy · 26 covering |
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
Used by most halal investing apps ✓ PASSES
The one Titan applies ✓ PASSES
What these two standards are, and how they differ →
- Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
- Debt load Interest-bearing debt is just 33.1% of its assets, well under the one-third ceiling — it does not run on borrowed money. Pass
- Interest-bearing cash Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit. Pass
- Receivables Money owed to the company is 16.8% of assets, under the 49% limit. Pass
- Revenue purity Only 0.0% of revenue comes from non-compliant sources — under the 5% line. Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
The business, in plain words · what the numbers mean
Surgeons pick the tools but investors pay the bill
Picture a hospital theatre where Stryker kits sit on every tray from joint replacements to navigation systems. The business clears a 13 percent profit margin and 15 percent ROE with a moderate moat, yet revenue is rising only 3 percent a year. At 19.1 times forward earnings the shares already sit above our fair value and the market is paying for growth that simply is not showing up.
We pass. The numbers do not justify stretching for the name when cheaper ways to own steady healthcare cash flows exist elsewhere. Analyst targets around 385 dollars reflect hope rather than the visible trajectory.
The main risk is that low growth plus a full valuation leaves little room for disappointment if hospital budgets tighten or competitors take share. Analysis, not advice.
| Forward P/E | 20.1x expensive even after accounting for its growth |
| Trailing P/E | 35.0x a premium valuation |
| Revenue growth | 9.4% steady growth |
| Profit margin | 14.4% thin but positive margins |
| Return on equity | 16.5% a solid return on shareholder capital |
| Debt to equity | 0.64 moderate, manageable leverage |
| Current ratio | 2.16 comfortably covers its short-term bills |
| Beta | 0.77 steadier than the market |
| Market cap | $129.3B |
| Employees | 56,000 |
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Latest news · what the market is reading on SYK
- › Stryker (SYK) Q2 2026 Earnings Call Transcript Motley Fool · 2d ago
- › Solventum (SOLV) Appoints Neil Zieselman As New Chief Accounting Officer Simply Wall St. · 3d ago
- › Is Stryker (SYK) Undervalued As Earnings Trigger A Fresh Valuation Question? Simply Wall St. · 4d ago
- › How Strong Q2 Earnings, Raised Guidance and Cyber Recovery Will Impact Stryker (SYK) Investors Simply Wall St. · 4d ago
- › SYK Q2 Deep Dive: Supply Chain Disruptions Weigh on Growth Outlook Despite Margin Expansion StockStory · 5d ago
Headlines from third-party outlets, linked for reference — not our reporting, not advice.
Related securities · others in SYK's space worth a look
Screened names in the same industry · explore each on its own page.
Where & how to trade · wherever in the world you are
SYK trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The trader read · the latest dated commentary
The dated journal · newest first, never edited
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 3.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 19%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (26 analysts) rates it buy, with a mean price target of $389.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The insider ledger · Form 4 filings, as filed
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-11 | FINK MARY KATHRYN | Officer | 8,720 | $2,473,756 | |
| 2026-05-08 | FINK MARY KATHRYN | Officer | 21,582 | $3,625,388 | |
| 2026-05-06 | MACEDA EMMANUEL PEREZ | Director | 762 | · | |
| 2026-05-06 | KING DEBRA | Chief Technology Officer | 1,016 | · | |
| 2026-05-06 | SKEETE TATUM LISA M | Director | 762 | · | |
| 2026-05-06 | CAFORIO GIOVANNI | Director | 762 | · | |
| 2026-05-06 | RUGGERI RACHEL | Director | 762 | · | |
| 2026-05-06 | MONTAGNINO KIMBERLY ANN | Officer | 677 | · | |
| 2026-05-06 | STRYKER RONDA E | Director | 762 | · | |
| 2026-05-06 | SILVERNAIL ANDREW K. | Director | 762 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
The political ledger · congressional disclosures
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-04-24 | Ro Khanna | Democrat | Purchase | 1K–15K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 15K–50K |
| 15 May2026 | Ro Khanna | Democrat | sell | 15K–50K |
| 1 May2026 | Ro Khanna | Democrat | buy | 15K–50K |
What holding actually paid · price plus dividends
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $282.58 | +9.3% | · | $1,093 | +9.3% |
| 2 months | $339.15 | -8.9% | · | $911 | -8.9% |
| 3 months | $336.30 | -8.2% | $0.88 | $921 | -7.9% |
| 6 months | $351.14 | -12.1% | $1.76 | $885 | -11.5% |
| 1 year | $381.37 | -19.0% | $3.44 | $819 | -18.1% |
| 2 years | $341.68 | -9.6% | $6.72 | $923 | -7.7% |
| 3 years | $272.59 | +13.3% | $9.82 | $1,169 | +16.9% |
| 5 years | $242.91 | +27.1% | $15.36 | $1,335 | +33.5% |
Historical returns from market close data. Past performance does not guarantee future results.